Literature DB >> 11194687

Comparison between vaginal misoprostol and cervical dinoprostone for cervical ripening and labor induction.

R Neiger1, P C Greaves.   

Abstract

OBJECTIVE: To compare the efficacy of intravaginal misoprostol (Cytotec) to intracervical dinoprostone (Prepidil) for pre-induction cervical ripening.
METHODS: Sixty-one patients admitted for induction of labor, whose cervices were unfavorable (Bishop score: 4), were randomly assigned to either intravaginal placement of a 50 micrograms misoprostol tablet or intracervical administration of dinoprostone gel.
RESULTS: Eighteen women (56%) in the misoprostol group and five (17%) in the dinoprostone group achieved cervical ripening within 12 hours (P = 0.007). Fewer doses of misoprostol were required to achieve cervical ripening, and the interval from induction of labor to delivery was shorter in the misoprostol group. Sixteen patients (50%) in the misoprostol group required oxytocin, whereas 26 (90%) in the dinoprostone group required oxytocin augmentation (P = 0.008). There was no significant difference in mode of delivery or neonatal outcome between the two groups.
CONCLUSION: Vaginal misoprostol appears to be a more effective cervical ripening agent than cervical dinoprostone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11194687

Source DB:  PubMed          Journal:  Tenn Med        ISSN: 1088-6222


  2 in total

Review 1.  Vaginal misoprostol for cervical ripening and induction of labour.

Authors:  G Justus Hofmeyr; A Metin Gülmezoglu; Cynthia Pileggi
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  A randomized controlled trial comparing isosorbide dinitrate-oxytocin versus misoprostol-oxytocin at management of foetal intrauterine death.

Authors:  Gabriel Arteaga-Troncoso; Aide E Chacon-Calderon; Francisco J Martinez-Herrera; Sylvia G Cruz-Nuñez; Marcela Lopez-Hurtado; Aurora Belmont-Gomez; Alberto M Guzman-Grenfell; Blanca E Farfan-Labonne; Carlos J Neri-Méndez; Francisco Zea-Prado; Fernando M Guerra-Infante
Journal:  PLoS One       Date:  2019-11-21       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.